Unknown

Dataset Information

0

Lorlatinib and Bevacizumab Activity in ALK-Rearranged Lung Cancers After Lorlatinib Progression.

ABSTRACT:

SUBMITTER: Choudhury NJ 

PROVIDER: S-EPMC7713518 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.
| S-EPMC6942925 | biostudies-literature
Unknown Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer.
| S-EPMC7904790 | biostudies-literature
Unknown Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.
| S-EPMC3385512 | biostudies-literature
Unknown New strategies for treatment of ALK-rearranged non-small cell lung cancers.
| S-EPMC3477548 | biostudies-literature
Unknown Monomerization of ALK Fusion Proteins as a Therapeutic Strategy in ALK-Rearranged Non-small Cell Lung Cancers.
| S-EPMC7142238 | biostudies-literature
Unknown The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers.
| S-EPMC5388194 | biostudies-literature
Unknown Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.
| S-EPMC5984716 | biostudies-literature
Unknown Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I/II study.
| S-EPMC8666648 | biostudies-literature
Unknown Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma.
| S-EPMC4770798 | biostudies-literature
Unknown A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on Crizotinib.
| S-EPMC9257415 | biostudies-literature